301 related articles for article (PubMed ID: 32736573)
1. ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.
Onweni CL; Zhang YS; Caulfield T; Hopkins CE; Fairweather L; Freeman WD
Crit Care; 2020 Jul; 24(1):475. PubMed ID: 32736573
[No Abstract] [Full Text] [Related]
2. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Rico-Mesa JS; White A; Anderson AS
Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
[TBL] [Abstract][Full Text] [Related]
3. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
[TBL] [Abstract][Full Text] [Related]
5. Drugs and the renin-angiotensin system in covid-19.
Aronson JK; Ferner RE
BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
[No Abstract] [Full Text] [Related]
6. The role of ACEIs/ARBs in COVID-19: Friend or foe?
Zhou Z; Qiu Y; Tao J
Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701
[No Abstract] [Full Text] [Related]
7. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
Huang Y; Xie C; Chen X; Hong Q; Huang H
Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
[No Abstract] [Full Text] [Related]
8. COVID-19: The heart of the issue.
Woodward B; Kermali M
J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
[No Abstract] [Full Text] [Related]
9. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
Patel AB; Verma A
JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
[No Abstract] [Full Text] [Related]
10. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
[TBL] [Abstract][Full Text] [Related]
11. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
Kai H; Kai M
Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular disease and the impact of COVID-19.
Yoganathan A; Sajjad MS; Harky A
J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
[No Abstract] [Full Text] [Related]
13. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR
J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565
[No Abstract] [Full Text] [Related]
14. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Young MJ; Clyne CD; Chapman KE
J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
[TBL] [Abstract][Full Text] [Related]
15. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
Lam KW; Chow KW; Vo J; Hou W; Li H; Richman PS; Mallipattu SK; Skopicki HA; Singer AJ; Duong TQ
J Infect Dis; 2020 Sep; 222(8):1256-1264. PubMed ID: 32702098
[TBL] [Abstract][Full Text] [Related]
16. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
Bean DM; Kraljevic Z; Searle T; Bendayan R; Kevin O; Pickles A; Folarin A; Roguski L; Noor K; Shek A; Zakeri R; Shah AM; Teo JTH; Dobson RJB
Eur J Heart Fail; 2020 Jun; 22(6):967-974. PubMed ID: 32485082
[TBL] [Abstract][Full Text] [Related]
18. Can beta-adrenergic blockers be used in the treatment of COVID-19?
Vasanthakumar N
Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
[No Abstract] [Full Text] [Related]
19. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
Rossi GP; Sanga V; Barton M
Elife; 2020 Apr; 9():. PubMed ID: 32250244
[TBL] [Abstract][Full Text] [Related]
20. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Pranata R; Permana H; Huang I; Lim MA; Soetedjo NNM; Supriyadi R; Soeroto AY; Alkatiri AA; Firman D; Lukito AA
Diabetes Metab Syndr; 2020; 14(5):983-990. PubMed ID: 32615377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
